HER2-Targeted ADCs in NSCLC: Redefining Treatment for HER2-Mutated Disease

In this section, the discussion shifts to therapeutic advances in HER2-mutated NSCLC, with a particular focus on antibody-drug conjugates (ADCs) as a transformative treatment modality. Drs. Santos and Lopes review key clinical trial data supporting the use of HER2-directed therapies, emphasizing meaningful improvements in response rates and durability compared with historical chemotherapy outcomes.

The faculty highlight the mechanism of action of ADCs, which combine HER2-targeting antibodies with cytotoxic payloads, enabling selective tumor delivery and enhanced efficacy. This approach is positioned as a major advancement in the management of HER2-driven lung cancer, particularly in previously treated patients.

Clinical efficacy endpoints such as objective response rate (ORR), progression-free survival (PFS), and duration of response (DoR) are discussed in the context of trial data. The speakers also note differences in toxicity profiles compared with traditional chemotherapy, including the need to monitor for interstitial lung disease (ILD) and other class-specific adverse events.

The discussion underscores that these therapies are reshaping the treatment landscape and are increasingly incorporated into guideline recommendations. HER2-targeted ADCs are becoming the new standard of care in later-line settings, with ongoing research exploring earlier-line use and combination strategies.